{"id":121476,"date":"2021-07-15T07:00:00","date_gmt":"2021-07-15T07:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=28920252892025"},"modified":"2021-07-15T07:00:00","modified_gmt":"2021-07-15T07:00:00","slug":"x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/","title":{"rendered":"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies"},"content":{"rendered":"<p><img decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"\" loading=\"lazy\" style=\"display: block; margin-bottom: 5px; clear:both;max-width: 100%;\" link_thumbnail=\"\" \/><\/p>\n<p><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter\" src=\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/X-Linked-Retinitis-Pigmentosa-XLRP-Market.jpg?1626327200098\" alt=\"X-Linked-Retinitis-Pigmentosa-XLRP-Market\" width=\"648\" height=\"270\" \/><\/p>\n<p>\u00a0<\/p>\n<p><span style=\"font-weight: 400;\">DelveInsight\u2019s <\/span><strong>X-Linked Retinitis Pigmentosa (XLRP) Market Insights Report<\/strong><span style=\"font-weight: 400;\"> offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into X-linked Retinitis Pigmentosa (XLRP) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward.\u00a0<\/span><\/p>\n<p><strong>Some of the key highlights from the <\/strong><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-Linked Retinitis Pigmentosa (XLRP) Market<\/strong><\/a><strong> Insights:\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">According to a study conducted by Ferrari et al. (2011), retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000\u20137000 people, and out of estimated percentages of RP types, there are 10\u201315% X-linked RP cases.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Some of the key companies profiled in the <\/span><strong>X-Linked Retinitis Pigmentosa therapeutics<\/strong><span style=\"font-weight: 400;\"> domain include <\/span><strong>Biogen, MeiraGTx Limited, Janssen Pharmaceuticals,\u00a0 Applied Genetic Technologies,<\/strong><span style=\"font-weight: 400;\"> and others.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">The dynamics of the X-Linked Retinitis Pigmentosa (XLRP) Market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world and the expected launch of emerging therapies during the forecast period.<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Of the emerging therapies, the most anticipated product to get approval is the gene therapy <\/span><strong>AAV-RPGR<\/strong><span style=\"font-weight: 400;\"> and <\/span><strong>NSR-RPGR<\/strong><span style=\"font-weight: 400;\">.\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><strong>AAV-RPGR<\/strong><span style=\"font-weight: 400;\"> a product being jointly developed by <\/span><strong>MeiraGTx Limited and Janssen Pharmaceuticals,<\/strong><span style=\"font-weight: 400;\"> it has been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (FDA), and PRIME, ATMP, and Orphan designations by the European Medicines Agency (EMA).<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">With many players actively engaged in the therapeutics development, the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>pipeline for X-Linked Retinitis Pigmentosa (XLRP)<\/strong><\/a><span style=\"font-weight: 400;\"> brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market for a study period 2018\u20132030.<\/span><\/li>\n<\/ul>\n<p><em><span style=\"font-weight: 400;\">Learn more by requesting for sample @ <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Market Landscape<\/em><\/strong><\/a><em><span style=\"font-weight: 400;\">\u00a0<\/span><\/em><\/p>\n<p><strong>X-Linked Retinitis Pigmentosa (XLRP): Overview<br \/>\n<\/strong><span style=\"font-weight: 400;\">X-linked Retinitis Pigmentosa is an inherited condition that leads to progressive vision loss predominantly in males. The condition begins with night blindness and can cause total loss of vision. According to DelveInsight\u2019s analysis, males are more affected as compared to females, in the case of X-linked Retinitis Pigmentosa. As per the study by Prokisch et al. (2007), \u201cthe real prevalence of XLRP affected males was approximately 1:15,000. The cumulated life risk of development of XLRP in carriers was strongly age-dependent and included one-third of the carriers older than 60 years\u201d.\u00a0<\/span><\/p>\n<p><em><span style=\"font-weight: 400;\">For more insights into Disease, causes, and treatment, reach out @ <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Treatment Landscape<\/em><\/strong><\/a><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>\u00a0X-Linked Retinitis Pigmentosa (XLRP) Epidemiology Segmentation<\/strong><\/a><\/p>\n<p><span style=\"font-weight: 400;\">The <\/span><strong>X-Linked Retinitis Pigmentosa (XLRP) Market<\/strong><span style=\"font-weight: 400;\"> report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Prevalent Cases of Retinitis Pigmentosa<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Diagnosed Prevalent Cases of X-linked Retinitis Pigmentosa<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Treatable Cases of X-linked Retinitis Pigmentosa<\/span><\/li>\n<\/ul>\n<p><em><span style=\"font-weight: 400;\">Visit for more @ <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Epidemiological Insights<\/em><\/strong><\/a><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-Linked Retinitis Pigmentosa (XLRP) Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">XLRP is an inherited condition and currently, there is no specific treatment. However, off-label therapies have been observed to provide a positive response in the treatment of patients with XLRP. Some of the therapeutics options such as the <\/span><strong>administration of vitamin A palmitate, lutein, calcium-channel blockers, and docosohexanoic acid <\/strong><span style=\"font-weight: 400;\">can potentially preserve the photoreceptor function.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">To provide an effective therapeutics solution companies worldwide are diligently working towards the development of new therapies and also exploring the possibilities of gene therapies for the XLRP. The expected launch of different gene therapies is expected to provide new dimensions to the XLRP treatment.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-Linked Retinitis Pigmentosa (XLRP) Pipeline Therapies and Key Companies<\/strong><span style=\"font-weight: 400;\">\u00a0<\/span><\/a><\/p>\n<ul>\n<li><strong>BIIB112 (NSR-RPGR)<\/strong> \u2013 Biogen<\/li>\n<li><strong>AAV-RPGR<\/strong> \u2013 MeiraGTx Limited\/Janssen Pharmaceuticals<\/li>\n<li><strong>AGTC-501 (rAAV2tYF-GRK1-RPGR)<\/strong> \u2013 Applied Genetic Technologies<\/li>\n<\/ul>\n<p><em><span style=\"font-weight: 400;\">For more information, visit <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Market Analysis, Patient Pool, and Emerging Therapies<\/em><\/strong><\/a><strong><em>\u00a0<\/em><\/strong><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-Linked Retinitis Pigmentosa (XLRP) Market Drivers<\/strong><\/a><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Increase in the patient population\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Expected launch of emerging therapies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Improvement in healthcare spending<\/span><\/li>\n<\/ul>\n<p><strong>Scope of the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">11 Years Forecast<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">7MM Coverage\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Descriptive overview of X-Linked Retinitis Pigmentosa (XLRP), covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Comprehensive insight into X-Linked Retinitis Pigmentosa (XLRP) epidemiology and treatment in the 7MM<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">Current and emerging therapies for X-Linked Retinitis Pigmentosa (XLRP)\u00a0<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">X-Linked Retinitis Pigmentosa (XLRP) market drivers and barriers\u00a0<\/span><\/li>\n<\/ul>\n<p><strong>Key Questions Answered in the Report<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What was the <\/span><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-Linked Retinitis Pigmentosa (XLRP) market share<\/strong><\/a><span style=\"font-weight: 400;\"> (%) distribution in 2018 and how it would look like in 2030?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What would be the X-Linked Retinitis Pigmentosa (XLRP) total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">What are the key findings pertaining to the market across 7MM and which country will have the largest X-Linked Retinitis Pigmentosa (XLRP) market size during the forecast period (2018-2030)?<\/span><\/li>\n<li style=\"font-weight: 400;\"><span style=\"font-weight: 400;\">At what CAGR, the X-Linked Retinitis Pigmentosa (XLRP) market is expected to grow in 7MM during the forecast period (2018-2030)?<\/span><\/li>\n<\/ul>\n<p><em><span style=\"font-weight: 400;\">Get in touch with our Business executive @ <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Market Landscape Analysis<\/em><\/strong><\/a><em><span style=\"font-weight: 400;\">\u00a0<\/span><\/em><\/p>\n<p><strong>Table of Contents\u00a0<\/strong><\/p>\n<table>\n<tbody>\n<tr>\n<td><strong>1<\/strong><\/td>\n<td><strong>Key Insights<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>2<\/strong><\/td>\n<td><strong>Report Introduction<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>3<\/strong><\/td>\n<td><strong>Competitive Intelligence Analysis for X-Linked Retinitis Pigmentosa (XLRP)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>4<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Market Overview at a Glance<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>5<\/strong><\/td>\n<td><strong>Executive Summary of X-Linked Retinitis Pigmentosa (XLRP)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>6<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Market Methodology<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>7<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Patient Population<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>8<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Patient Journey<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>9<\/strong><\/td>\n<td><strong>Treatment Algorithm, Current Treatment, and Medical Practices<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>10<\/strong><\/td>\n<td><strong>Key Endpoints in X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>11<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Marketed Therapies\u00a0<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>12<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Emerging Therapies<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>13<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP): 7 Major Market Analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>14<\/strong><\/td>\n<td><strong>Attribute analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>15<\/strong><\/td>\n<td><strong>Access and Reimbursement Overview of X-Linked Retinitis Pigmentosa (XLRP)<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>16<\/strong><\/td>\n<td><strong>KOL Reviews<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>17<\/strong><\/td>\n<td><strong>Case Reports<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>18<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Market Drivers<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>19<\/strong><\/td>\n<td><strong>X-Linked Retinitis Pigmentosa (XLRP) Market Barriers<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>20<\/strong><\/td>\n<td><strong>SWOT Analysis<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>21<\/strong><\/td>\n<td><strong>Disclaimer<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>22<\/strong><\/td>\n<td><strong>DelveInsight Capabilities<\/strong><\/td>\n<\/tr>\n<tr>\n<td><strong>23<\/strong><\/td>\n<td><strong>About DelveInsight<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em><span style=\"font-weight: 400;\">Learn more about the report offerings @ <\/span><\/em><a href=\"https:\/\/www.delveinsight.com\/sample-request\/x-linked-retinitis-pigmentosa-market?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong><em>X-Linked Retinitis Pigmentosa (XLRP) Market Outlook<\/em><\/strong><\/a><\/p>\n<p><strong>Related Reports<\/strong><span style=\"font-weight: 400;\"> \u2013<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/x-linked-retinitis-pigmentosa-pipeline-insight?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>X-linked Retinitis Pigmentosa Pipeline Insight<\/strong><span style=\"font-weight: 400;\"><br \/>\n<\/span><\/a><span style=\"font-weight: 400;\">X-linked Retinitis Pigmentosa Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the X-linked Retinitis Pigmentosa market.<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/corneal-endothelial-dystrophy-market\"><strong>Corneal Endothelial Dystrophy Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cCorneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Corneal Endothelial Dystrophy market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/electroencephelographs-eeg-pipeline-insight-and-competitive-landscape\"><strong>Electroencephelographs (EEG) Pipeline Insight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s, \u201cElectroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,\u201d report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/lymphatic-malformations-market\"><strong>Lymphatic Malformations Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cLymphatic Malformations Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Lymphatic Malformations market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/bevacizumab-biosimilars-insight\"><strong>Bevacizumab Biosimilars Insight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s, \u201cBevacizumab\u2013 Biosimilar Insight, 2020,\u201d report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\u00a0<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pyelonephritis-market\"><strong>Acute Pyelonephritis Market<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight\u2019s \u201cAcute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030\u201d report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/span><\/p>\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/?utm_source=SatPR&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"><strong>Healthcare Blogs<\/strong><\/a><strong> \u2013\u00a0<\/strong><\/p>\n<ul>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>JAK inhibitors Pipeline<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/diabetic-macular-edema-therapy-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Diabetic Macular Edema Market Developments<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/implantable-cardiac-monitors-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Implantable Cardiac Monitors Market Growth<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/neurovascular-thrombectomy-devices-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Neurovascular Thrombectomy Devices Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/vagus-nerve-stimulator-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Vagus Nerve Stimulator Market Share<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/pros-and-cons-of-wearable-devices\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Wearable Technology Advantages and Disadvantages<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/age-related-hearing-loss-device-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Age-Related Hearing Loss Devices Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/technology-and-autism-spectrum-disorder\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Impact of Technology on People with Autism<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/eye-disorders-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Common Eye Diseases and Treatments<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/medical-device-2021\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Leading Medtech Companies<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/presbyopia-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Key Companies in the Presbyopia Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/spinal-stenosis-devices-market-size\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Spinal Stenosis Devices Market Share<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><a href=\"https:\/\/www.delveinsight.com\/blog\/bone-cancer-treatment-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\"><strong>Bone Cancer Therapeutics Market<\/strong><\/a><\/li>\n<li style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Cardiac Monitoring Devices Market<\/a><\/strong><\/li>\n<li style=\"font-weight: 400;\"><strong><a href=\"https:\/\/www.delveinsight.com\/blog\/skin-cancer-treatment-market-and-key-companies\/?utm_source=blog&#038;utm_medium=promotion&#038;utm_campaign=blog\">Pharma Companies in Skin Cancer Market<\/a><\/strong><\/li>\n<\/ul>\n<p><strong>Get in touch with our Business executive for<\/strong><a href=\"https:\/\/www.delveinsight.com\/consulting\/competitive-intelligence-services?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"> <strong>Competitive Intelligence Services<\/strong><\/a><\/p>\n<p><strong>About<\/strong><a href=\"https:\/\/www.delveinsight.com\/?utm_source=Icrowd&#038;utm_medium=pressrelease&#038;utm_campaign=rpr\"> <strong>DelveInsight<\/strong><\/a><br \/>\n<span style=\"font-weight: 400;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform<\/span><a href=\"https:\/\/www.pharmdelve.com\/?utm_source=gnw&#038;utm_medium=pr&#038;utm_campaign=vpr\"> <strong>PharmDelve<\/strong><\/a><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><strong>Connect With Us at<\/strong><a href=\"https:\/\/www.linkedin.com\/company\/delveinsight-business-research-llp\/\"> <strong>LinkedIn<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/www.facebook.com\/delveinsightindia\/\"><strong> Facebook<\/strong><\/a><strong> |<\/strong><a href=\"https:\/\/twitter.com\/delve_insight\"><strong> Twitter<\/strong><\/a><\/p>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Shruti Thakur info@delveinsight.com +91-9650213330<\/p>\n<\/p>\n<\/div>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\">X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\">Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; DelveInsight&rsquo;s X-Linked Retinitis Pigmentosa (XLRP) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into X-linked Retinitis Pigmentosa (XLRP) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies [&hellip;]<\/p>\n<p>The post <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\">X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies &ndash; Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies<\/a> appeared first on <a rel=\"nofollow\" href=\"https:\/\/heymuse.com\/\">Financial Market Brief<\/a>.<\/p>\n<p> <a href=\"https:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-121476","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business\" \/>\n<meta property=\"og:description\" content=\"&nbsp; DelveInsight&rsquo;s X-Linked Retinitis Pigmentosa (XLRP) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into X-linked Retinitis Pigmentosa (XLRP) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies [&hellip;] The post X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies &ndash; Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies appeared first on Financial Market Brief. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-15T07:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\",\"name\":\"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"datePublished\":\"2021-07-15T07:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/","og_locale":"en_US","og_type":"article","og_title":"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business","og_description":"&nbsp; DelveInsight&rsquo;s X-Linked Retinitis Pigmentosa (XLRP) Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into X-linked Retinitis Pigmentosa (XLRP) market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies [&hellip;] The post X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies &ndash; Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies appeared first on Financial Market Brief. Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/","og_site_name":"Business","article_published_time":"2021-07-15T07:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/","url":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/","name":"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","datePublished":"2021-07-15T07:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/05\/5353-Delveinsight.png"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/07\/15\/x-linked-retinitis-pigmentosa-xlrp-market-to-advance-owing-to-the-continuous-therapeutics-developments-by-key-companies-biogen-meiragtx-limited-janssen-pharmaceuticals-and-applied-genet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"X-Linked Retinitis Pigmentosa (XLRP) Market to Advance Owing to the Continuous Therapeutics Developments by Key Companies \u2013 Biogen, MeiraGTx Limited, Janssen Pharmaceuticals, and Applied Genetic Technologies"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/121476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=121476"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/121476\/revisions"}],"predecessor-version":[{"id":121477,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/121476\/revisions\/121477"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=121476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=121476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=121476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}